{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:26:55Z","timestamp":1791260815297,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300606"],"award-info":[{"award-number":["32300606"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Breast cancer is the most prevalent type of malignant tumor among women. Here, we identified transcription factor CP2-like 1 (TFCP2L1) as a suppressor of breast cancer cells. Patients with breast cancer have poorer prognoses when\n                    <jats:italic>TFCP2L1<\/jats:italic>\n                    is expressed at low levels. Consistently, the expression of\n                    <jats:italic>TFCP2L1<\/jats:italic>\n                    is greater in normal breast tissues and cells than in breast cancer tissues and cell lines. Gain- and loss-of-function experiments and xenograft tumor assays revealed that overexpression of\n                    <jats:italic>TFCP2L1<\/jats:italic>\n                    significantly inhibited the proliferation and migration of breast cancer cells. Conversely, the knockdown of\n                    <jats:italic>TFCP2L1<\/jats:italic>\n                    promoted the growth and migration of breast cancer cells. Mechanistically, TFCP2L1 suppresses breast cancer progression by inhibiting the expression of glutathione peroxidase 4 (\n                    <jats:italic>GPX4<\/jats:italic>\n                    ), a key positive regulator of ferroptosis. Therefore, the addition of a ferroptosis inhibitor, Ferrostatin-1, can mediate the function of TFCP2L1 in breast cancer cells. On the other hand, high-throughput transcriptome sequencing revealed that\n                    <jats:italic>TFCP2L1<\/jats:italic>\n                    negatively regulates the activity of the PI3K\/AKT signaling pathway. The administration of SC79, an AKT activator, partially reversed the negative effects of TFCP2L1 on\n                    <jats:italic>GPX4<\/jats:italic>\n                    transcription. Together, these findings indicate that TFCP2L1 functions partially by directly and indirectly regulating\n                    <jats:italic>GPX4<\/jats:italic>\n                    -mediated ferroptosis and may serve as a potential therapeutic target for breast cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41420-026-03231-7","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:07:28Z","timestamp":1782475648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TFCP2L1 suppresses breast cancer progression by promoting ferroptosis through direct and PI3K\/AKT-mediated inhibition of GPX4"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8496-4875","authenticated-orcid":false,"given":"Xiaoxiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8851-3427","authenticated-orcid":false,"given":"Yuanzhi","family":"Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1864-8561","authenticated-orcid":false,"given":"Shou-Dong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9404-5933","authenticated-orcid":false,"given":"Xiangfen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"3231_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288\u2013300.","journal-title":"JAMA"},{"key":"3231_CR2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.7150\/ijbs.21635","volume":"13","author":"YS Sun","year":"2017","unstructured":"Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017;13:1387\u201397.","journal-title":"Int J Biol Sci"},{"key":"3231_CR3","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1056\/NEJM199810013391407","volume":"339","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974\u201384.","journal-title":"N Engl J Med"},{"key":"3231_CR4","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1002\/cncr.34499","volume":"128","author":"MB Nierengarten","year":"2022","unstructured":"Nierengarten MB. Cancer survivorship increases while disparities persist: Recent cancer survivorship statistics estimate cancer survivor prevalence and, for the first time, include treatment patterns by race and ethnicity for several cancer types: Recent cancer survivorship statistics estimate cancer survivor prevalence and, for the first time, include treatment patterns by race and ethnicity for several cancer types. Cancer. 2022;128:3754.","journal-title":"Cancer"},{"key":"3231_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06148-6","volume":"14","author":"Q Chen","year":"2023","unstructured":"Chen Q, Hu Q, Chen Y, Shen N, Zhang N, Li A, et al. PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer. Cell Death Dis. 2023;14:655.","journal-title":"Cell Death Dis"},{"key":"3231_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30105-0","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Qu J, Qi Y, Duan Y, Huang YW, Zhou Z, et al. EZH2 engages TGFbeta signaling to promote breast cancer bone metastasis via integrin beta1-FAK activation. Nat Commun. 2022;13:2543.","journal-title":"Nat Commun"},{"key":"3231_CR7","doi-asserted-by":"publisher","first-page":"215904","DOI":"10.1016\/j.canlet.2022.215904","volume":"548","author":"T Li","year":"2022","unstructured":"Li T, Zhai D, Zhang M, Ye R, Kuang X, Shao N, et al. KIF17 maintains the epithelial phenotype of breast cancer cells and curbs tumour metastasis. Cancer Lett. 2022;548:215904.","journal-title":"Cancer Lett"},{"key":"3231_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","volume":"35","author":"F Yang","year":"2023","unstructured":"Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2023;35:84\u2013100 e108.","journal-title":"Cell Metab"},{"key":"3231_CR9","doi-asserted-by":"publisher","first-page":"16779","DOI":"10.1007\/s00432-023-05423-5","volume":"149","author":"TC Cheng","year":"2023","unstructured":"Cheng TC, Wu JH, Zhu B, Gao HY, Zheng L, Chen WX. Identification of a novel five ferroptosis-related gene signature as a promising prognostic model for breast cancer. J Cancer Res Clin Oncol. 2023;149:16779\u201395.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3231_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08341-2","volume":"21","author":"D Wang","year":"2021","unstructured":"Wang D, Wei G, Ma J, Cheng S, Jia L, Song X, et al. Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients. BMC Cancer. 2021;21:645.","journal-title":"BMC Cancer"},{"key":"3231_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.cell.2018.01.029","volume":"172","author":"SA Lambert","year":"2018","unstructured":"Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, et al. The Human Transcription Factors. Cell. 2018;172:650\u201365.","journal-title":"Cell"},{"key":"3231_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.stem.2012.02.016","volume":"10","author":"Z Wang","year":"2012","unstructured":"Wang Z, Oron E, Nelson B, Razis S, Ivanova N. Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell. 2012;10:440\u201354.","journal-title":"Cell Stem Cell"},{"key":"3231_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s12282-018-0844-x","volume":"25","author":"JM Zhang","year":"2018","unstructured":"Zhang JM, Wei K, Jiang M. OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer. Breast Cancer. 2018;25:447\u201355.","journal-title":"Breast Cancer"},{"key":"3231_CR14","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/onc.2011.338","volume":"31","author":"O Leis","year":"2012","unstructured":"Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31:1354\u201365.","journal-title":"Oncogene"},{"key":"3231_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018;173:338\u201354 e315.","journal-title":"Cell"},{"key":"3231_CR16","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1038\/emboj.2013.175","volume":"32","author":"S Ye","year":"2013","unstructured":"Ye S, Li P, Tong C, Ying QL. Embryonic stem cell self-renewal pathways converge on the transcription factor Tfcp2l1. EMBO J. 2013;32:2548\u201360.","journal-title":"EMBO J"},{"key":"3231_CR17","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1038\/emboj.2013.177","volume":"32","author":"G Martello","year":"2013","unstructured":"Martello G, Bertone P, Smith A. Identification of the missing pluripotency mediator downstream of leukaemia inhibitory factor. EMBO J. 2013;32:2561\u201374.","journal-title":"EMBO J"},{"key":"3231_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.stemcr.2015.07.014","volume":"5","author":"D Qiu","year":"2015","unstructured":"Qiu D, Ye S, Ruiz B, Zhou X, Liu D, Zhang Q, et al. Klf2 and Tfcp2l1, Two Wnt\/beta-Catenin Targets, Act Synergistically to Induce and Maintain Naive Pluripotency. Stem Cell Rep. 2015;5:314\u201322.","journal-title":"Stem Cell Rep"},{"key":"3231_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2018.01.078","volume":"420","author":"G Kotarba","year":"2018","unstructured":"Kotarba G, Krzywinska E, Grabowska AI, Taracha A, Wilanowski T. TFCP2\/TFCP2L1\/UBP1 transcription factors in cancer. Cancer Lett. 2018;420:72\u201379.","journal-title":"Cancer Lett"},{"key":"3231_CR20","doi-asserted-by":"publisher","first-page":"e10696","DOI":"10.1371\/journal.pone.0010696","volume":"5","author":"HW Tun","year":"2010","unstructured":"Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS ONE. 2010;5:e10696.","journal-title":"PLoS ONE"},{"key":"3231_CR21","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1007\/s40618-024-02392-5","volume":"47","author":"C Zeng","year":"2024","unstructured":"Zeng C, Zhang Y, Lin C, Liang W, Chen J, Chen Y, et al. TFCP2L1, a potential differentiation regulator, predicts favorable prognosis and dampens thyroid cancer progression. J Endocrinol Invest. 2024;47:2953\u201368.","journal-title":"J Endocrinol Invest"},{"key":"3231_CR22","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910880","volume":"12","author":"J Heo","year":"2020","unstructured":"Heo J, Noh BJ, Lee S, Lee HY, Kim Y, Lim J, et al. Phosphorylation of TFCP2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis. EMBO Mol Med. 2020;12:e10880.","journal-title":"EMBO Mol Med"},{"key":"3231_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01789-9","volume":"22","author":"J Yang","year":"2023","unstructured":"Yang J, Bergdorf K, Yan C, Luo W, Chen SC, Ayers GD, et al. CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth. Mol Cancer. 2023;22:92.","journal-title":"Mol Cancer"},{"key":"3231_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-024-00534-1","volume":"13","author":"D Qiu","year":"2024","unstructured":"Qiu D, Wang T, Xiong Y, Li K, Qiu X, Feng Y, et al. TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG\/STAT3 pathway in hepatocellular carcinoma. Oncogenesis. 2024;13:33.","journal-title":"Oncogenesis"},{"key":"3231_CR25","doi-asserted-by":"publisher","first-page":"6944","DOI":"10.1002\/jcp.26483","volume":"233","author":"H Sun","year":"2018","unstructured":"Sun H, You Y, Guo M, Wang X, Zhang Y, Ye S. Tfcp2l1 safeguards the maintenance of human embryonic stem cell self-renewal. J Cell Physiol. 2018;233:6944\u201351.","journal-title":"J Cell Physiol"},{"key":"3231_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:88.","journal-title":"Cell Death Dis"},{"key":"3231_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1507\/endocrj.EJ20-0806","volume":"68","author":"X Li","year":"2021","unstructured":"Li X, Yang S, Zhao C, Yang J, Li C, Shen W, et al. CircHACE1 functions as a competitive endogenous RNA to curb differentiated thyroid cancer progression by upregulating Tfcp2L1 through adsorbing miR-346. Endocr J. 2021;68:1011\u201325.","journal-title":"Endocr J"},{"key":"3231_CR28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s12276-022-00786-0","volume":"54","author":"J Heo","year":"2022","unstructured":"Heo J, Lee J, Nam YJ, Kim Y, Yun H, Lee S, et al. The CDK1\/TFCP2L1\/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer. Exp Mol Med. 2022;54:801\u201311.","journal-title":"Exp Mol Med"},{"key":"3231_CR29","doi-asserted-by":"publisher","first-page":"188890","DOI":"10.1016\/j.bbcan.2023.188890","volume":"1878","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W. GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. Biochim Biophys Acta Rev Cancer. 2023;1878:188890.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3231_CR30","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"3231_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171:273\u201385.","journal-title":"Cell"},{"key":"3231_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","volume":"66","author":"B Zhou","year":"2020","unstructured":"Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol. 2020;66:89\u2013100.","journal-title":"Semin Cancer Biol"},{"key":"3231_CR33","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.2147\/DDDT.S472178","volume":"18","author":"Y Luo","year":"2024","unstructured":"Luo Y, Bai XY, Zhang L, Hu QQ, Zhang N, Cheng JZ, et al. Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches. Drug Des Devel Ther. 2024;18:2485\u2013529.","journal-title":"Drug Des Devel Ther"},{"key":"3231_CR34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41392-023-01606-1","volume":"8","author":"S Sun","year":"2023","unstructured":"Sun S, Shen J, Jiang J, Wang F, Min J. Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transd Target Ther. 2023;8:372.","journal-title":"Signal Transd Target Ther"},{"key":"3231_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.09.014","volume":"522","author":"Y Lu","year":"2021","unstructured":"Lu Y, Qin H, Jiang B, Lu W, Hao J, Cao W, et al. KLF2 inhibits cancer cell migration and invasion by regulating ferroptosis through GPX4 in clear cell renal cell carcinoma. Cancer Lett. 2021;522:1\u201313.","journal-title":"Cancer Lett"},{"key":"3231_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.canlet.2021.04.007","volume":"510","author":"L Liu","year":"2021","unstructured":"Liu L, Li Y, Cao D, Qiu S, Li Y, Jiang C, et al. SIRT3 inhibits gallbladder cancer by induction of AKT-dependent ferroptosis and blockade of epithelial-mesenchymal transition. Cancer Lett. 2021;510:93\u2013104.","journal-title":"Cancer Lett"},{"key":"3231_CR37","doi-asserted-by":"publisher","first-page":"216935","DOI":"10.1016\/j.canlet.2024.216935","volume":"593","author":"F Yao","year":"2024","unstructured":"Yao F, Zhou S, Zhang R, Chen Y, Huang W, Yu K, et al. CRISPR\/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma. Cancer Lett. 2024;593:216935.","journal-title":"Cancer Lett"},{"key":"3231_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.tcb.2020.02.009","volume":"30","author":"BR Stockwell","year":"2020","unstructured":"Stockwell BR, Jiang X, Gu W. Emerging Mechanisms and Disease Relevance of Ferroptosis. Trends Cell Biol. 2020;30:478\u201390.","journal-title":"Trends Cell Biol"},{"key":"3231_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K\/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193\u2013204.","journal-title":"Cancer Treat Rev"},{"key":"3231_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","volume":"4","author":"J Luo","year":"2003","unstructured":"Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257\u201362.","journal-title":"Cancer Cell"},{"key":"3231_CR41","first-page":"9081","volume":"8","author":"Y Sun","year":"2015","unstructured":"Sun Y, Xu Y, Xu J, Lu D, Wang J. Role of TM4SF1 in regulating breast cancer cell migration and apoptosis through PI3K\/AKT\/mTOR pathway. Int J Clin Exp Pathol. 2015;8:9081\u20138.","journal-title":"Int J Clin Exp Pathol"},{"key":"3231_CR42","doi-asserted-by":"publisher","first-page":"121986","DOI":"10.1016\/j.biomaterials.2022.121986","volume":"294","author":"W Jiang","year":"2023","unstructured":"Jiang W, Zhong S, Chen Z, Qian J, Huang X, Zhang H, et al. 2D-CuPd nanozyme overcome tamoxifen resistance in breast cancer by regulating the PI3K\/AKT\/mTOR pathway. Biomaterials. 2023;294:121986.","journal-title":"Biomaterials"},{"key":"3231_CR43","doi-asserted-by":"publisher","first-page":"31189","DOI":"10.1073\/pnas.2017152117","volume":"117","author":"J Yi","year":"2020","unstructured":"Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA. 2020;117:31189\u201397.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3231_CR44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/cjp2.325","volume":"9","author":"J Li","year":"2023","unstructured":"Li J, Jiang JL, Chen YM, Lu WQ. KLF2 inhibits colorectal cancer progression and metastasis by inducing ferroptosis via the PI3K\/AKT signaling pathway. J Pathol Clin Res. 2023;9:423\u201335.","journal-title":"J Pathol Clin Res"},{"key":"3231_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12860-022-00424-7","volume":"23","author":"K Wang","year":"2022","unstructured":"Wang K, He J, Tu C, Xu H, Zhang X, Lv Y, et al. Upregulation of CCT3 predicts poor prognosis and promotes cell proliferation via inhibition of ferroptosis and activation of AKT signaling in lung adenocarcinoma. BMC Mol Cell Biol. 2022;23:25.","journal-title":"BMC Mol Cell Biol"},{"key":"3231_CR46","doi-asserted-by":"publisher","first-page":"103035","DOI":"10.1016\/j.redox.2024.103035","volume":"70","author":"M Shen","year":"2024","unstructured":"Shen M, Cao S, Long X, Xiao L, Yang L, Zhang P, et al. DNAJC12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of AKT. Redox Biol. 2024;70:103035.","journal-title":"Redox Biol"},{"key":"3231_CR47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00432-024-05658-w","volume":"150","author":"M Guo","year":"2024","unstructured":"Guo M, Liu M, Li W, Wang C, Zhang L, Zhang H. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k\/Akt\/mTOR pathway. J Cancer Res Clin Oncol. 2024;150:155.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3231_CR48","doi-asserted-by":"publisher","first-page":"122395","DOI":"10.1016\/j.biomaterials.2023.122395","volume":"303","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhou K, Lin J, Yao X, Ju D, Zeng X, et al. Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles. Biomaterials. 2023;303:122395.","journal-title":"Biomaterials"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03231-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:32:24Z","timestamp":1789090344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03231-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3231"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03231-7","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments involving the use of animals were approved by the Institutional Animal Care and Use Committee of the University of Science and Technology of China (Protocol No: 2024-N(A)-001). All procedures performed in this study on normal and cancerous human breast tissue samples were in accordance with the ethical standards of the Institutional Ethics Committee of the University of Science and Technology of China (Protocol No: 2024KY-329). Written informed consent was obtained from all patients prior to the operation.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"364"}}